"Finding shell stocks with mergers in the works"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The way this is being held down with iron shackels almost, is a sure sign that something of truly epic proportions is brewing! I've been in this in and out since 0.0006 watching whole time, this not trading like a normal stock at all all the signs pointing to something....perhaps BMSN was even dragged down to 0.0002 for this very reason something big in the making hold on to your shares for dear life!
Seems like it has always been held down! Must be a good reason for that! I have a hard time otherwise understanding all this shorting. You don't under typical circumstances short a stock with pending news and certainly when news was released unless something truly epic is going on. This may also explain why Koos let this go pink and held back the 10-k?!
Only way to explain this holding down is group trying to accumilate for big run or promo group trying to get as many cheap shares before promo. Then when it runs they take all the credit even though this was going to run regardless.
This time around I think the game has changed slightly. Before it was working with speculation now it's operating on news!
Any chance mm's missed the news-wire of IND and sold millions short? Is their trading based on algorithms so this was traded purely from charts...? News-wire was kinda sudden and out of the blue middle of morning...
Any idea why there would be this kind of selling? On news for that matter?! Millions were sold....what's going on here????? Was the news disappointing?
What's happening now with this dip is surgical and very good people had huge ask stacking that had to be broken for this to run to pennyland
Fake-out territory trying to shake the weak before the really big run yet to come!
Why is entb still listed as limited? Aren't they current now?
I'm guessing Friday will see the price soar after these two days of heavy consolidation. Today is probably the last chance to get in for a steal!
Just mm's flushing out the weak hands by bringing it down back up then down.....don't you see the pattern already?! As soon as all the sellers are out they will bring this to a new high, just watch.....
I couldn't have stated it better myself! Each time I tried flipping I had to buy higher later! And yes this is certainly no pump and dump! This is based on IND news which the past news-wire said is CURENTLY in preparation!
Pink companies such as BMSN became on the 15th of this month don't need to be current and file 10-k that is the way it works. I would be surprised if it comes in the near future. The company is more flexible and agile this way. No worries here!
Nice consolidation from yesterday's huge gains. Huge buys today at mid 30's I think we will see the price move up soon and close even or slightly lower. We might even close green?!
For al those looking at ask grow.....it is purely a scare tactic to get people to sell shares cheaper.....
IND stands for investigate new drug. It is permission from the FDA to do clinical testing. See my post "read the bold"
Newswire that IND is currently in preparation! Read my post intiltled "read the bold"
I'm back in news came out! IND is coming soon!
Read the bold!
http://www.marketwire.com/press-release/regen-biopharma-peer-reviewed-publication-provides-preclinical-support-hemaxellerate-pinksheets-bmsn-1749531.htm
SOURCE: Bio-Matrix Scientific Group, Inc.
January 24, 2013 14:53 ET
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate™ Bone Marrow Failure Product
Bio-Matrix Subsidiary's Publication Is Scientific Basis for IND Submission Currently in Preparation
Thats right in preperation!
SAN DIEGO, CA--(Marketwire - Jan 24, 2013) - Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate™ bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.
HemaXellerate™ is a cell therapy product developed by Regen BioPharma that uses fat derived from the patient as a source of "healing cells" to stimulate bone marrow production of blood cells. These "healing cells" are termed "endothelial cells" and are a critical component of the blood production machinery of the bone marrow that is damaged in patients with bone marrow failure.
Intellectual property covering the HemaXellerate™ product include US Provisional Patent applications 61/648898 - Acceleration of Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells and 61/670791 - Treatment of Hematopoietic Disorders filed by Regen, as well as an option to exclusively license issued US Patent #6,821,513.
Currently, the only way to stimulate production of blood from bone marrow is through administration of growth factors. The overall market for growth factors is $18 billion per year. Unfortunately, growth factors require repeated administration, are expensive, and in many patients are ineffective.
"Treatments available today for patients with insufficient bone marrow function are a 'band-aid' solution that require repeated administration and do not address the underlying cause of bone marrow failure," said David Koos, Chairman and CEO of Bio-Matrix, and a co-author of the publication. "We believe that HemaXellerate™ offers the possibility to actually heal damage that has occurred to the bone marrow and thus more naturally treat the core of cause of bone marrow inactivity."
The publication contained data obtained from independent laboratories supporting the use of HemaXellerate™ as an alternative to growth factor therapy and was a co-authored by stem cell pioneers Dr. Amit Patel from University of Utah, and Dr. Michael Murphy from Indiana University. Additionally, the paper was co-authored by companies working in the field of stem cells including Cook Biotechnology and Medistem, Inc.
Regen BioPharma's first indication of HemaXellerate™ will be patients with aplastic anemia who are drug resistant and not eligible for bone marrow transplantation. Demonstration of efficacy in this patient population is anticipated to lead the way for entry into the $18 billion hematopoietic growth factor market which includes conditions such as anemia, thrombocytopenia, and chemotherapy associated leukopenia.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks
Contact Information
Contact:
Bio-Matrix Scientific Group, Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.bmsn.us
Email Contact
Nice post!
In response to your suggestion as to why the website is down I would offer the following I got when I visited their site:
Bandwidth Limit Exceeded
The server is temporarily unable to service your request due to the site owner reaching his/her bandwidth limit. Please try again later.
Apache Server at www.bmsn.us Port 80
Terry, you make a lot of bold statements here with supposed facts such as PPS that Hicks got 0.0003?!
Whats a non reporting pink never heard of that all pinks that are non current are listed as limited info and BMSN is currently listed as such?!
Show some evidence or documentation to support what your saying!
Btw, did you short BMSN by any chance?!
How do you know about this:
There is a hedge fund in control.
My guess is mm's will paint the closing at 0.0022 so they can cover lower on Monday...
What does that mean could you explain? Thanks!
Power up hour is coming...............!!!!!!!!!!!!!!!!!!!!!
I think you mean the 15th which was 2 weeks late that already passed so the stock is no on pink as opposed to otcb
What 2 week extension I didn't see any filing for that?
Why the 29th pinks aren't fully reporting....
How much dilution here whats the OS and AS?
News yesterday was a prelude to the massive dilution that started again today.....
Big debt and lots of dilution here why do you say that?
Getting slammed here how low will it go?
Anyone know the current debt standing?
Liquidity and Capital Resources
We have incurred a net loss of $16.3 million for the nine months ended September 30, 2012, and $14.0 million for the year ended December 31, 2011, and have an accumulated deficit of $73.2 million as of September 30, 2012. Based on our operating plan, our existing working capital will not be sufficient to meet the cash requirements to fund our planned operating expenses, capital expenditures and working capital requirements through December 31, 2012 without additional sources of cash.
In order to provide and preserve the necessary working capital to operate, we have successfully completed the following transactions in 2012:
•
Entered into an Exchange Agreement with Magna Group LLC (“Magna”), pursuant to which we agreed to issue to Magna convertible notes, in the aggregate principal amount of up to $4.6 million, in exchange for repayment of our Term Loan with Compass Horizon Funding Company, LLC.
•
Obtained a Forbearance Agreement on our semi-annual coupon payment due on June 1, 2012 with certain holders of our Senior Subordinated Notes to defer payment until December 1, 2012.
•
Reduced future interest payments through executing an Exchange Agreement for $2.5 million with certain holders of our Senior Subordinated Notes for conversion of their Notes and accrued interest into shares at an exchange rate of one share of our common stock for each $1.00 amount of the Note and accrued interest.
•
Issued 6,375,000 shares of our common stock to an institutional investor in settlement of approximately $1.3 million of our outstanding accounts payable balances.
•
Completed a Registered Direct offering to issue 1,000,000 shares of common stock at $0.50 per share for gross proceeds of $0.5 million.
•
Obtained unsecured short-term convertible debt financing of $0.6 million with additional availability of approximately $0.6 million at the lender’s sole discretion.
•
Returned unused raw materials to our suppliers in exchange for refunds net of restocking charges of approximately $0.3 million.
Do you know what the current A/S is?
I'm out! dilution over her is out of control. even if they get a good check OS is close to 500 million now. not much room to move up.
will hit 0.10 today....
How much can the market capitalization be already?
What about 2012?!
Ask not budging price is at the ask!
Still in denial of any dilution?!